DNA Nanobots Raises $3.5M to Advance Non-Viral Gene Therapy Platform Using DNA Origami Technology
核心洞察
DNA Nanobots (搜索) secured $3.5 million in funding from a family office to advance its self-assembling nanoscale therapeutics platform over the next 18 months.
The company utilizes DNA origami (搜索) technology to engineer nanobots that deliver therapeutic payloads directly to diseased cells with unprecedented specificity while minimizing systemic toxicity.
Funding will support pre-clinical studies, production capabilities expansion, IP portfolio development, and strategic hiring to prepare for IND-enabling studies.
DNA Nanobots (搜索), a Columbus-based biotechnology company pioneering self-assembling nanoscale therapeutics, announced it has secured $3.5 million in funding from a prominent family office. The investment provides an 18-month operational runway and represents completion of the majority of the company's targeted $5 million seed funding round.
The Ohio State University spinout is developing a novel gene therapy (搜索) platform that utilizes DNA origami (搜索) technology to create programmable, non-viral gene delivery systems. According to the company, these nanobots are engineered to carry and release therapeutic payloads directly to diseased cells with unprecedented specificity, minimizing systemic toxicity while maximizing treatment efficacy.
"We are very pleased to have successfully completed $3.5 million of our $5 million Seed round," said Jim Lynch, CEO of DNA Nanobots (搜索). "This financing provides the capital needed to advance our programs and execute key value-creating milestones in 2026."
Platform Technology and Applications
DNA Nanobots (搜索) positions itself as addressing genes that are considered undeliverable through conventional gene therapy (搜索) approaches. The company's platform relies on precise DNA self-assembly, also known as DNA origami (搜索), to construct nanobots designed for targeted therapeutic delivery.
The technology represents a departure from viral vector-based gene therapies, instead utilizing self-assembling DNA structures to create what the company describes as programmable delivery vehicles. These nanobots are designed to deliver therapeutic payloads with cell-specific targeting capabilities.
Funding Allocation and Development Plans
The $3.5 million investment will be allocated across four primary areas of development. The company plans to advance pre-clinical studies to further optimize and test the efficacy of its self-assembling nanobot designs. Additionally, funding will support expansion of production capabilities through strengthened in-house manufacturing infrastructure, enabling larger batch runs and improved reproducibility.
DNA Nanobots (搜索) also intends to expand its intellectual property portfolio surrounding the core technology platform and recruit specialized talent in molecular biology, nanotechnology, and engineering.
Path to Clinical Development
With the anchor investment secured, DNA Nanobots (搜索) is actively seeking to complete its seed funding round by raising an additional $1.5 million. The completion of the full $5 million seed round will enable the company to initiate IND-enabling studies and fully prepare for its first-in-human clinical trials.
The funding timeline positions the company to reach key development milestones in 2026, according to Lynch's statements regarding value-creating objectives for the coming year.
Ohio Life Sciences Ecosystem
The investment reflects broader confidence in Ohio's life sciences sector, according to Eddie Pauline, President and CEO of Ohio Life Sciences Association (搜索). "We're excited to see Ohio Life Sciences member DNA Nanobots (搜索) secure $3.5 million in funding, a strong signal of confidence in Ohio's life sciences ecosystem," Pauline said. "It's encouraging to see capital flowing into Ohio-based companies, including innovative Ohio State spinouts that showcase the strength of our research, commercialization, and homegrown innovation."
The company's development as an Ohio State University spinout highlights the university's role in translating academic research into commercial biotechnology ventures within the state's growing life sciences sector.